This article is a correction to:
Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
Wen-Hsuan Tsai
Fung-Chang Sung
Lu-Ting Chiu
Ying-Hsiu Shih
Ming-Chieh Tsai1
Shu-I Wu- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
- 2Management Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taipei, Taiwan
- 3Department of Health Services Administration, China Medical University, College of Public Health, Taichung, Taiwan
- 4Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan
- 5Department of Medicine, Mackay Medical College, New Taipei City, Taiwan
- 6Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan
A corrigendum on
Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
by Tsai, W.-H., Sung, F.-C., Chiu, L.-T., Shih, Y.-H., Tsai, M.-C., and Wu, S.-I. (2022). Front. Pharmacol. 13:765446. doi: 10.3389/fphar.2022.765446
In the original article, there was an error in the Results section. The following paragraph was written incorrectly:
Both groups were similar in age and gender distributions, with a mean age of 53.33 years (SD 13.04) and 45.06% women (Table 1). Most baseline prevalence rates of comorbidities were significantly higher in GLP1-RA users than non-users, except for malignancy and alcoholic liver disease. The uses of other hypoglycemic agents were more prevalent in GLP1-RA users than non-users. The GLP1-RA group also had higher aDCSI scores, higher percentages of white-collar jobs and lived more in more urbanized areas.
This paragraph has been corrected to read as follows:
“Both groups had similar distributions of age, gender, occupation, urbanization and comorbidities, with a mean age of 53.33 years (SD 13.04) and 45.06% women (Table 1). Although, the percentage of using metformin was higher in non-GLP1-RA users.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: neuroendocrine, diabetes, glucagon-like peptide-1 receptor agonist, depression, anxiety
Citation: Tsai W-, Sung F-, Chiu L-, Shih Y-, Tsai M- and Wu S- (2022) Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study. Front. Pharmacol. 13:886343. doi: 10.3389/fphar.2022.886343
Received: 28 February 2022; Accepted: 07 March 2022;
Published: 22 March 2022.
Edited and reviewed by:
Dominique Massotte, Université de Strasbourg, FranceCopyright © 2022 Tsai, Sung, Chiu, Shih, Tsai and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shu-I Wu, dDE0MEBtbWMuZWR1LnR3
†These authors have contributed equally to this work